QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)

Anika Therapeutics (ANIK) Stock Forecast, Price & News

$18.63
-0.25 (-1.32%)
(As of 09/29/2023 ET)
Compare
Today's Range
$18.41
$19.03
50-Day Range
$16.98
$25.45
52-Week Range
$16.54
$32.51
Volume
113,383 shs
Average Volume
121,779 shs
Market Capitalization
$272.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
26.1% Upside
$23.50 Price Target
Short Interest
Bearish
6.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.12
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.78) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

799th out of 972 stocks

Surgical & Medical Instruments Industry

84th out of 101 stocks


ANIK stock logo

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Price History

ANIK Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Q2 2023 Anika Therapeutics Inc Earnings Call
Hemostatic Agents Market Research | 2023-2030
ANIK Anika Therapeutics, Inc.
Barrington Keeps Their Hold Rating on Anika Therapeutics (ANIK)
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Company Calendar

Last Earnings
8/08/2023
Today
9/29/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
345
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$23.50
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+26.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-14,860,000.00
Pretax Margin
-16.56%

Debt

Sales & Book Value

Annual Sales
$156.24 million
Cash Flow
$0.49 per share
Book Value
$19.55 per share

Miscellaneous

Free Float
13,775,000
Market Cap
$272.56 million
Optionable
Optionable
Beta
0.78

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Cheryl Renee Blanchard Ph.D. (Age 59)
    Pres, CEO & Director
    Comp: $1.31M
  • Mr. Michael L. LevitzMr. Michael L. Levitz (Age 49)
    Exec. VP, CFO & Treasurer
    Comp: $710.6k
  • Mr. David Colleran J.D. (Age 51)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $664.54k
  • Ms. Anne Nunes (Age 54)
    Sr. VP & COO
  • Mr. Ian W. McLeod
    VP & Chief Accounting Officer
  • Mr. Mark Namaroff (Age 60)
    Exec. Director of Investor Relations & Corp. Communications
  • Mr. James Chase
    Sr. VP of International Sales & Marketing
  • Mr. Ben Joseph
    VP of Commercial & Corp. Devel.
  • Ms. Lisa Funiciello
    VP of HR













ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price forecast for 2023?

2 analysts have issued twelve-month price objectives for Anika Therapeutics' stock. Their ANIK share price forecasts range from $23.00 to $24.00. On average, they predict the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 26.1% from the stock's current price.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2023?

Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 37.1% and is now trading at $18.63.
View the best growth stocks for 2023 here
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ANIK earnings forecast
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) released its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.21. The biotechnology company had revenue of $44.30 million for the quarter, compared to analysts' expectations of $40.61 million. Anika Therapeutics had a negative net margin of 13.68% and a negative trailing twelve-month return on equity of 3.53%.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $159.50 million-$163.00 million, compared to the consensus revenue estimate of $161.84 million.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $18.63.

How much money does Anika Therapeutics make?

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $272.56 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Anika Therapeutics have?

The company employs 345 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -